DDW Highlights: 17 March 2026

The latest Mayo Clinic analysis reveals that the Parkinson‑related protein alpha‑synuclein dramatically accelerates tau accumulation in women with Alzheimer’s disease. In a cohort of 415 participants, those with abnormal alpha‑synuclein showed up to twenty‑fold faster brain changes, offering a molecular explanation for the two‑thirds female prevalence of dementia. Understanding this sex‑specific interaction opens new avenues for biomarkers and therapeutic targets, positioning alpha‑synuclein as a critical factor in precision neurology and highlighting the urgency of gender‑focused research in neurodegeneration.

Parallel advances aim to modify disease pathways rather than merely observe them. At Texas A&M, extracellular vesicle (EV) therapy derived from stem cells is being tested to re‑program microglia, the brain’s immune cells, reducing chronic inflammation that fuels Alzheimer’s progression. Meanwhile, researchers at the Institute of Cancer Research have launched an MRI‑driven preclinical platform that faithfully reproduces pediatric high‑grade glioma biology, enabling rapid assessment of drug penetration across an intact blood‑brain barrier. These complementary strategies—cell‑derived vesicles to calm neuroinflammation and imaging‑guided models to accelerate oncology drug discovery—illustrate how translational tools are reshaping therapeutic pipelines.

On the oncology front, a newly identified vulnerability in triple‑negative breast cancer involves aberrant activation of the germ‑cell gene Hormad1, which compromises chromosome stability. Inhibitors of Aurora B, MPS1 and BUB1 have shown pre‑clinical efficacy, suggesting a targeted route for a disease that lacks approved therapies. In infectious disease, a European Union‑funded trial now compares the standard maternal RSV vaccine with the long‑acting monoclonal antibody niservimab, probing whether combined passive‑active immunisation offers superior infant protection. Together, these discoveries underscore a shift toward mechanism‑driven interventions across neurodegeneration, cancer, and viral prevention.